US FDA APPROVES BYDUREON® PEN (EXENATIDE EXTENDED-RELEASE FOR INJECTABLE SUSPENSION) FOR ONCE-WEEKLY TREATMENT OF ADULTS with TYPE 2 DIABETES
Drug shortages continue to pose patient safety risks and challenge providers, according to Premier, Inc. survey
Mylan Fourth Quarter 2013 Adjusted Diluted EPS Increases 20% to $0.78 and Full Year Adjusted Diluted EPS Increases 12% to $2.89
Lilly's Once-Weekly Dulaglutide Shows Non-Inferiority to Liraglutide in Head-to-Head Phase III Trial for Type 2 Diabetes
Once-Weekly Dulaglutide Hits Primary Endpoint in Sixth Consecutive AWARD Trial
Ventana Medical Systems, Inc., Convenes International Patient Safety Advisory Board To Advance Standard Of Care And Reduce Risk Of Misdiagnosis
TUCSON, Ariz., Feb. 25, 2014 /PRNewswire/ -- Ventana Medical Systems, Inc.